Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 120

recruiting
3 987
countries
28
conditions
2 109

4 235 trials match your criteria

Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Lutetium (177LU) vipivotide tetraxetan

Study on Lasofoxifene, Fulvestrant, and Abemaciclib for Advanced Breast Cancer in Women and Men with ESR1 Mutation

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib

Study Comparing Telisotuzumab Vedotin and Docetaxel for Adults with Previously Treated Non-Squamous Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel

Study on Ibrutinib and Venetoclax for Patients with Untreated Chronic Lymphocytic Leukemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib

Study on Long-Term Safety of Inclisiran for Patients with Familial Hypercholesterolemia Who Completed Previous Adolescent Studies

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Inclisiran

Efficacy and Safety of Givinostat for Non-Ambulant Patients with Duchenne Muscular Dystrophy

Investigational
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Givinostat

Study of Fluoroestradiol F-18 and Biomarkers for Women with ER-Positive HER2-Negative Metastatic Breast Cancer After CDK4/6 Inhibitor Therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Fluoroestradiol F-18

Study on the Effectiveness and Safety of Dapirolizumab Pegol for Patients with Moderate to Severe Systemic Lupus Erythematosus

Registered drug
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Anhydrous Caffeine

Study on Early Detection of Triple-Negative Breast Cancer Relapse Using 68Ga-FAPI-46 for Patients at High Risk

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:(S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate

Study on Olaparib for Patients with p53abn Endometrial Cancer After Chemoradiation Therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib

Study on the Long-Term Safety of Dapirolizumab Pegol for Patients with Systemic Lupus Erythematosus

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Anhydrous Caffeine
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.